All‐cause mortality · adults with cirrhosis and gastroesophageal varices
Carvedilol showed no clear difference in mortality compared with traditional, non‐selective beta‐blockers (low certainty).
1 finding from 1 review
Upper gastrointestinal bleeding · adults with cirrhosis and gastroesophageal varices
It is very uncertain whether carvedilol changes upper gastrointestinal bleeding compared with traditional, non‐selective beta‐blockers (very low certainty).
1 finding from 1 review
Serious adverse events · adults with cirrhosis and gastroesophageal varices
Carvedilol showed no clear difference in serious adverse events compared with traditional, non‐selective beta‐blockers (low certainty).
1 finding from 1 review
Non‐serious adverse events · adults with cirrhosis and gastroesophageal varices
It is very uncertain whether carvedilol changes non‐serious adverse events compared with traditional, non‐selective beta‐blockers (very low certainty).
1 finding from 1 review
Hepatic venous pressure gradient at end of treatment (mmHg) · adults with cirrhosis and gastroesophageal varices
1 finding from 1 review
Reduction in hepatic venous pressure gradient (%) · adults with cirrhosis and gastroesophageal varices
1 finding from 1 review
Haemodynamic treatment failure · adults with cirrhosis and gastroesophageal varices
It is very uncertain whether carvedilol changes haemodynamic treatment failure compared with traditional, non‐selective beta‐blockers (very low certainty).
1 finding from 1 review
All‐cause mortality · heart failure in patients with Chagas cardiomyopathy
It is very uncertain whether carvedilol changes all‐cause mortality compared with placebo (very low certainty).
1 finding from 1 review
Cardiac mortality · heart failure in patients with Chagas cardiomyopathy
1 finding from 1 review
Time to heart decompensation · heart failure in patients with Chagas cardiomyopathy
1 finding from 1 review
Disease‐free period at 30, 60 and 90 days · heart failure in patients with Chagas cardiomyopathy
1 finding from 1 review
Overall survival · heart failure in patients with Chagas cardiomyopathy
1 finding from 1 review
Quality of life · heart failure in patients with Chagas cardiomyopathy
1 finding from 1 review
Adverse events · heart failure in patients with Chagas cardiomyopathy
It is very uncertain whether carvedilol changes adverse events compared with placebo (very low certainty).
1 finding from 1 review